The Experts below are selected from a list of 51 Experts worldwide ranked by ideXlab platform

Christopher C. Welch - One of the best experts on this subject based on the ideXlab platform.

  • Anaphylaxis from medroxyprogesterone acetate.
    Obstetrics & Gynecology, 2004
    Co-Authors: Daniel O. Selo-ojeme, Amna Tillisi, Christopher C. Welch
    Abstract:

    BACKGROUND: More than 30 million women in more than 90 countries use depot medroxyprogesterone acetate as an Injectable Contraceptive Agent, and it is thought to be very safe. However, it should be recognized that serious and potentially life-threatening adverse effects can occur. CASE: A 40-year-old para 2 went into anaphylactic shock after receiving 150 mg of depot medroxyprogesterone acetate intramuscularly. She was not taking any other medication, and there was no history of allergy to food or cosmetics. She responded fully to immediate resuscitation. A repeat episode occurred when she received another dose 12 weeks later. CONCLUSION: Although thought to be very safe, life-threatening adverse effects can occur with depot medroxyprogesterone acetate, and practitioners should be prepared for such eventuality.

  • Anaphylaxis from medroxyprogesterone acetate.
    Obstetrics and gynecology, 2004
    Co-Authors: Daniel O. Selo-ojeme, Amna Tillisi, Christopher C. Welch
    Abstract:

    More than 30 million women in more than 90 countries use depot medroxyprogesterone acetate as an Injectable Contraceptive Agent, and it is thought to be very safe. However, it should be recognized that serious and potentially life-threatening adverse effects can occur. A 40-year-old para 2 went into anaphylactic shock after receiving 150 mg of depot medroxyprogesterone acetate intramuscularly. She was not taking any other medication, and there was no history of allergy to food or cosmetics. She responded fully to immediate resuscitation. A repeat episode occurred when she received another dose 12 weeks later. Although thought to be very safe, life-threatening adverse effects can occur with depot medroxyprogesterone acetate, and practitioners should be prepared for such eventuality.

Catherine Cansino - One of the best experts on this subject based on the ideXlab platform.

  • Injectable Contraception: Current Practices and Future Trends
    Current Obstetrics and Gynecology Reports, 2015
    Co-Authors: Kristen Wolfe, Catherine Cansino
    Abstract:

    Injectable contraception includes progestin-only and combined estrogen and progestin Agents that provide safe and highly effective birth control for one to three months. Injectable Agents are widely available and play an important role in family planning programs worldwide. Depot medroxyprogesterone acetate, available for intramuscular injection and subcutaneous injection, is the best known and most broadly distributed Injectable Contraceptive Agent, and is an ideal Agent for women who have contraindications to estrogen use. Despite their effectiveness, progestin-only Injectables are associated with high rates of discontinuation due to bothersome side effects including abnormal bleeding, health controversies including decreased bone mineral density, and increased risk of human immunodeficiency virus acquisition. Injectables do offer non-Contraceptive benefits including symptom control related to endometriosis and fibroids, and decreased risk of endometrial cancer. Research is ongoing to determine new Injectable hormone formulations that provide longer-acting Contraceptive protection and fewer side effects.

Daniel O. Selo-ojeme - One of the best experts on this subject based on the ideXlab platform.

  • Anaphylaxis from medroxyprogesterone acetate.
    Obstetrics & Gynecology, 2004
    Co-Authors: Daniel O. Selo-ojeme, Amna Tillisi, Christopher C. Welch
    Abstract:

    BACKGROUND: More than 30 million women in more than 90 countries use depot medroxyprogesterone acetate as an Injectable Contraceptive Agent, and it is thought to be very safe. However, it should be recognized that serious and potentially life-threatening adverse effects can occur. CASE: A 40-year-old para 2 went into anaphylactic shock after receiving 150 mg of depot medroxyprogesterone acetate intramuscularly. She was not taking any other medication, and there was no history of allergy to food or cosmetics. She responded fully to immediate resuscitation. A repeat episode occurred when she received another dose 12 weeks later. CONCLUSION: Although thought to be very safe, life-threatening adverse effects can occur with depot medroxyprogesterone acetate, and practitioners should be prepared for such eventuality.

  • Anaphylaxis from medroxyprogesterone acetate.
    Obstetrics and gynecology, 2004
    Co-Authors: Daniel O. Selo-ojeme, Amna Tillisi, Christopher C. Welch
    Abstract:

    More than 30 million women in more than 90 countries use depot medroxyprogesterone acetate as an Injectable Contraceptive Agent, and it is thought to be very safe. However, it should be recognized that serious and potentially life-threatening adverse effects can occur. A 40-year-old para 2 went into anaphylactic shock after receiving 150 mg of depot medroxyprogesterone acetate intramuscularly. She was not taking any other medication, and there was no history of allergy to food or cosmetics. She responded fully to immediate resuscitation. A repeat episode occurred when she received another dose 12 weeks later. Although thought to be very safe, life-threatening adverse effects can occur with depot medroxyprogesterone acetate, and practitioners should be prepared for such eventuality.

Kristen Wolfe - One of the best experts on this subject based on the ideXlab platform.

  • Injectable Contraception: Current Practices and Future Trends
    Current Obstetrics and Gynecology Reports, 2015
    Co-Authors: Kristen Wolfe, Catherine Cansino
    Abstract:

    Injectable contraception includes progestin-only and combined estrogen and progestin Agents that provide safe and highly effective birth control for one to three months. Injectable Agents are widely available and play an important role in family planning programs worldwide. Depot medroxyprogesterone acetate, available for intramuscular injection and subcutaneous injection, is the best known and most broadly distributed Injectable Contraceptive Agent, and is an ideal Agent for women who have contraindications to estrogen use. Despite their effectiveness, progestin-only Injectables are associated with high rates of discontinuation due to bothersome side effects including abnormal bleeding, health controversies including decreased bone mineral density, and increased risk of human immunodeficiency virus acquisition. Injectables do offer non-Contraceptive benefits including symptom control related to endometriosis and fibroids, and decreased risk of endometrial cancer. Research is ongoing to determine new Injectable hormone formulations that provide longer-acting Contraceptive protection and fewer side effects.

Owen P Phillips - One of the best experts on this subject based on the ideXlab platform.

  • new aspects of Injectable contraception
    International journal of fertility and women's medicine, 2001
    Co-Authors: Owen P Phillips
    Abstract:

    Despite the availability of efficacious and safe Contraceptive Agents not all womens Contraceptive needs are being met. An Injectable Contraceptive method offers convenience and encourages compliance both very important aspects for women seeking ideal contraception. Depot medroxyprogesterone acetate (DMPA) is a long-acting Injectable and is highly effective; one injection provides 3 months of contraception. Drawbacks of DMPA include irregular bleeding and a slow return to fertility. A new monthly Injectable Contraceptive Agent is medroxyprogesterone acetate/estradiol cypionate suspension (Lunelle). It provides menstrual regulation and a rapid return to fertility. The estrogen ensures a withdrawal bleed monthly; however women with contraindications to estrogen-containing contraception are not candidates for Lunelle. (authors)